Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis

Immunocheckpoint inhibitors (ICIs) have become a standard pharmacological therapy in non‐small cell lung cancer (NSCLC). Because brain metastases (BMs) have historically been listed as exclusion criteria in previous clinical trials involving ICIs in advanced NSCLC, the survival benefit from ICI in N...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamori, Shinkichi, Komiya, Takefumi, Powell, Emily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897968/
https://www.ncbi.nlm.nih.gov/pubmed/33340271
http://dx.doi.org/10.1002/cam4.3675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897968/
https://www.ncbi.nlm.nih.gov/pubmed/33340271
http://dx.doi.org/10.1002/cam4.3675

Ejemplares similares